Gastrointestinal stromal tumors: The 2015 asco News

Gastrointestinal stromal tumors (GISTs) were discussed within the framework of educational sections, as well as within the discussions holding on special communications after oral and poster papers, at the 2015 American Society of Clinical Oncology ASCO Annual Meeting in June, in Chicago.The most interesting studies were devoted to estimating efficiency and the optimal duration of imatinib adjuvant therapy in patients at high risk for disease progression and finding effective new drugs to treat patients with GISTs, which had resistance to traditional tyrosine kinase inhibitors.In the section of estimating efficiency of imatinib adjuvant therapy the most interesting studies were presented by H.Joensuu, - the second planned analysis of the randomized SSGXVIII/AIO trial, and C.Raut - the results of non-randomized 3-year patients observation study (PERSIST-5) concerning the efficiency of imatinib adjuvant treatment during 5 years in patients with high-risk disease development. In the second section of most interest was the oral report of the J.-Y.Blay - the results of multicenter randomized study - PAZOGIST, phase II, associated with the efficacy of pazopanib, as well as the study of Ping Chi devoted to estimating efficiency of the combination of MEK inhibitors (binimetinib) and KIT (imatinib) and M.Heinrich devoted to estimating efficiency of ponatinib in patients with GISTs, which had resistance to traditional tyrosine kinase inhibitors.

ASCO 2015, GISTs, imatinib, pazopanib, binimetinib, ponatinib